Additional Proxy Soliciting Materials (definitive) (defa14a)
June 22 2022 - 9:04AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
Proxy
Statement Pursuant to Section 14(a) of the
Securities
Exchange Act of 1934
Filed
by the Registrant ☒ Filed by a Party other than the Registrant ☐
☐ |
Preliminary
Proxy Statement |
|
|
☐ |
Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
|
☐ |
Definitive
Proxy Statement |
|
|
☒ |
Definitive
Additional Materials |
|
|
☐ |
Soliciting
Material under §240.14a-12 |
Provectus
Biopharmaceuticals, Inc.
(Name of registrant as specified in its charter)
(Name of person(s) filing proxy statement, if other than the registrant)
Payment of Filing Fee (Check the appropriate box):
☒ |
No
fee required |
|
|
☐ |
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11 |
|
(1) |
Title
of each class of securities to which transaction applies: |
|
|
|
|
|
|
|
(2) |
Aggregate
number of securities to which transaction applies: |
|
|
|
|
|
|
|
(3) |
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined): |
|
|
|
|
|
|
|
(4) |
Proposed
maximum aggregate value of transaction: |
|
|
|
|
|
|
|
(5) |
Total
fee paid: |
|
|
|
|
|
|
☐ |
Fee
paid previously with preliminary materials. |
☐ |
Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its
filing. |
|
|
|
|
(1) |
Amount
Previously Paid: |
|
|
|
|
|
|
|
(2) |
Form,
Schedule or Registration Statement No.: |
|
|
|
|
|
|
|
(3) |
Filing
Party: |
|
|
|
|
|
|
|
(4) |
Date
Filed: |
|
|
|
During
its annual meeting of stockholders to be held on June 22, 2022, Provectus Biopharmaceuticals, Inc. (the “Company”) will provide
an update about the Company’s clinical development, regulatory affairs, drug discovery, manufacturing, intellectual property, business
development, and corporate development activities.
A
copy of the Company’s 2022 Annual Meeting of Stockholders presentation slides is attached.
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024